Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

personalised medicines

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma

The treatment showed a significant improvement in overall survival versus placebo

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia

Patients with chronic ITP may live with an increased risk of severe bleeding events

- PMLiVE

Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation

Phase 3 trial results of Zeposia showed statistically significant results in response and remission

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

BeiGene’s Brukinsa gets green light from NICE as Waldenström’s macroglobulinemia treatment

The condition occurs in less than 2% of patients with non-Hodgkin lymphomas

- PMLiVE

NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment

The drug will not be available as a treatment option for men with prostate cancer in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links